Next Article in Journal
The Role of Cerl2 in the Establishment of Left-Right Asymmetries during Axis Formation and Heart Development
Next Article in Special Issue
Function of Adenylyl Cyclase in Heart: the AKAP Connection
Previous Article in Journal
The Physiopathology of Cardiorenal Syndrome: A Review of the Potential Contributions of Inflammation
Previous Article in Special Issue
Phosphodiesterases 3 and 4 Differentially Regulate the Funny Current, If, in Mouse Sinoatrial Node Myocytes
Open AccessFeature PaperReview

The Potential of a Novel Class of EPAC-Selective Agonists to Combat Cardiovascular Inflammation

1
Institute of Chemical Sciences, Heriot-Watt University, Edinburgh EH14 4AS, UK
2
Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
3
Institute of Biological Chemistry, Biophysics and Bioengineering, Heriot-Watt University, Edinburgh EH14 4AS, UK
*
Author to whom correspondence should be addressed.
J. Cardiovasc. Dev. Dis. 2017, 4(4), 22; https://doi.org/10.3390/jcdd4040022
Received: 7 November 2017 / Revised: 23 November 2017 / Accepted: 30 November 2017 / Published: 5 December 2017
(This article belongs to the Special Issue Cyclic Nucleotide Signaling and the Cardiovascular System)
The cyclic 3′,5′-adenosine monophosphate (cAMP) sensor enzyme, EPAC1, is a candidate drug target in vascular endothelial cells (VECs) due to its ability to attenuate proinflammatory cytokine signalling normally associated with cardiovascular diseases (CVDs), including atherosclerosis. This is through the EPAC1-dependent induction of the suppressor of cytokine signalling gene, SOCS3, which targets inflammatory signalling proteins for ubiquitinylation and destruction by the proteosome. Given this important role for the EPAC1/SOCS3 signalling axis, we have used high throughput screening (HTS) to identify small molecule EPAC1 regulators and have recently isolated the first known non-cyclic nucleotide (NCN) EPAC1 agonist, I942. I942 therefore represents the first in class, isoform selective EPAC1 activator, with the potential to suppress pro-inflammatory cytokine signalling with a reduced risk of side effects associated with general cAMP-elevating agents that activate multiple response pathways. The development of augmented I942 analogues may therefore provide improved research tools to validate EPAC1 as a potential therapeutic target for the treatment of chronic inflammation associated with deadly CVDs. View Full-Text
Keywords: EPAC1; cyclic AMP; cyclic nucleotide binding domain; inflammation; endothelial cells; high-throughput screening EPAC1; cyclic AMP; cyclic nucleotide binding domain; inflammation; endothelial cells; high-throughput screening
Show Figures

Figure 1

MDPI and ACS Style

Barker, G.; Parnell, E.; Van Basten, B.; Buist, H.; Adams, D.R.; Yarwood, S.J. The Potential of a Novel Class of EPAC-Selective Agonists to Combat Cardiovascular Inflammation. J. Cardiovasc. Dev. Dis. 2017, 4, 22.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop